Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2022.6051
Abstract: Importance Lipid pathways have been implicated in the pathogenesis of psoriasis, and some lipid-lowering drugs, such as statins, are hypothesized to have disease-modifying properties. However, large population-level studies are scarce, and causal interpretation of results… read more here.
Keywords: lowering drugs; risk psoriasis; lipid lowering; risk ... See more keywords
The Pro12Ala polymorphism of PPARγ2 modulates beta cell function and failure to oral glucose‐lowering drugs in patients with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes/Metabolism Research and Reviews"
DOI: 10.1002/dmrr.3392
Abstract: We evaluate whether the Pro12Ala polymorphism of peroxisome proliferator‐activated receptor γ2 (PPARγ2) has a role in the progression of diabetes by modulating the occurrence of treatment failure to glucose‐lowering drugs. read more here.
Keywords: ppar; failure; lowering drugs; pro12ala polymorphism ... See more keywords
Real world evidence of clinical predictors of glycaemic response to glucose‐lowering drugs among Chinese with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2023 at "Diabetes/Metabolism Research and Reviews"
DOI: 10.1002/dmrr.3615
Abstract: To examine whether simple clinical features can predict the 1‐year glycaemic response to glucose‐lowering drugs (GLDs) among Chinese with type 2 diabetes. read more here.
Keywords: lowering drugs; glucose lowering; among chinese; chinese type ... See more keywords
Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2.
Sign Up to like & getrecommendations! Published in 2020 at "Advances in experimental medicine and biology"
DOI: 10.1007/5584_2020_514
Abstract: Diabetes mellitus is constantly increasing worldwide. Vascular complications are the most common in the setting of long-standing disease, claiming the greatest burden in terms of morbidity and mortality. Glucotoxicity is involved in vascular damage through… read more here.
Keywords: control; glycaemic control; lowering drugs; diabetes mellitus ... See more keywords
Glucose-Lowering Drugs and Fracture Risk—a Systematic Review
Sign Up to like & getrecommendations! Published in 2020 at "Current Osteoporosis Reports"
DOI: 10.1007/s11914-020-00638-8
Abstract: Diabetes mellitus (DM) is associated with increased fracture risk. The aim of this systematic review was to examine the effects of different classes of glucose-lowering drugs on fracture risk in patients with type 2 DM.… read more here.
Keywords: drugs fracture; fracture; lowering drugs; fracture risk ... See more keywords
Effects of evolving lipid-lowering drugs on carbohydrate metabolism.
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes research and clinical practice"
DOI: 10.1016/j.diabres.2017.12.012
Abstract: The understanding that statins reduce but not eliminate the cardiovascular risk associated with disturbed lipid metabolism and the existence of forms of dyslipidemia that are unresponsive or only partially responsive to statins have led to… read more here.
Keywords: drugs carbohydrate; effects evolving; metabolism; lowering drugs ... See more keywords
Are current dietary guidelines relevant to subjects on cholesterol-lowering drugs?
Sign Up to like & getrecommendations! Published in 2019 at "Proceedings of the Nutrition Society"
DOI: 10.1017/s0029665119000685
Abstract: The present paper reviews the evidence as to whether patients on lipid-lowering drugs should restrict dietary SFA intake. Premature mortality from atherosclerotic CVD has fallen dramatically in many high-income countries. This appears to be due… read more here.
Keywords: lowering drugs; sfa intake; cholesterol; dietary sfa ... See more keywords
Safety and tolerability of available urate-lowering drugs: a critical review
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2019.1594771
Abstract: ABSTRACT Introduction: Urate-lowering therapy (ULT) is the cornerstone of gout management, which is a widespread chronic illness characterized by hyperuricemia, arthropathy, tophus development, and urolithiasis. Since asymptomatic increased serum urate levels are associated with a… read more here.
Keywords: safety tolerability; safety; lowering drugs; urate lowering ... See more keywords
4113Glucose lowering drugs or strategies, major adverse cardiovascular events and heart failure outcomes, and association with weight loss - meta-analysis of large cardiovascular outcome trials
Sign Up to like & getrecommendations! Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz745.0117
Abstract: Glucose lowering drugs or strategies (GLDS) have varied effects on major adverse cardiovascular events (MACE) and heart failure (HF) in cardiovascular outcomes trials. Mechanisms driving cardiovascular risk reduction remain elusive. We searched MEDLINE, PubMed, and… read more here.
Keywords: heart; heart failure; lowering drugs; cardiovascular ... See more keywords
Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Hypertension"
DOI: 10.1097/hjh.0000000000001720
Abstract: Objective: To systematically evaluate the efficacy of five commonly used blood pressure-lowering drugs in reducing cardiovascular events among patients with nonacute cardiovascular disease, but without heart failure. Methods: We searched PubMed, EMBASE, and Cochrane Central… read more here.
Keywords: blood pressure; disease; lowering drugs; pressure lowering ... See more keywords
Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American Association of Nurse Practitioners"
DOI: 10.1097/jxx.0000000000000126
Abstract: ABSTRACT To provide an overview of cardiovascular outcome trials (CVOT) with once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs), and other recent CVOTs, and to discuss the implications for the management of patients with type 2 diabetes… read more here.
Keywords: cardiovascular outcome; lowering drugs; type diabetes; outcome trials ... See more keywords